181 related articles for article (PubMed ID: 15601560)
1. [Clinical analysis of rituximab combined with chemotherapy in treating aggressive B-cell non-Hodgkin's lymphoma].
Zhang HY; Lin TY; Jiang WQ; Zhang L; Huang HQ; Xia ZJ; Sun XF; He YJ; Guan ZZ
Ai Zheng; 2004 Dec; 23(12):1681-6. PubMed ID: 15601560
[TBL] [Abstract][Full Text] [Related]
2. Immunochemotherapy: the new standard in aggressive non-Hodgkin's lymphoma in the elderly.
Coiffier B
Semin Oncol; 2003 Feb; 30(1 Suppl 2):21-7. PubMed ID: 12652461
[TBL] [Abstract][Full Text] [Related]
3. The clinical features, therapeutic responses, and prognosis of the patients with mantle cell lymphoma.
Ying ZT; Zheng W; Wang XP; Xie Y; Tu MF; Lin NJ; Ping LY; Liu WP; Deng LJ; Zhang C; Zhu J; Song YQ
Chin J Cancer; 2012 Jul; 31(7):348-53. PubMed ID: 22704490
[TBL] [Abstract][Full Text] [Related]
4. Pixantrone beyond monotherapy: a review.
Barrenetxea Lekue C; Grasso Cicala S; Leppä S; Stauffer Larsen T; Herráez Rodríguez S; Alonso Caballero C; Jørgensen JM; Toldbod H; Leal Martínez I; D'Amore F
Ann Hematol; 2019 Sep; 98(9):2025-2033. PubMed ID: 31312929
[TBL] [Abstract][Full Text] [Related]
5. Chemotherapy combinations with monoclonal antibodies in non-Hodgkin's lymphoma.
Kahl B
Semin Hematol; 2008 Apr; 45(2):90-4. PubMed ID: 18381103
[TBL] [Abstract][Full Text] [Related]
6. Rituximab-combined anthracycline-free chemotherapy in newly diagnosed paediatric and adolescent patients with non-high-risk aggressive mature B cell lymphoma: protocol for a single-arm, open-label, multicentre, phase II study (the Japan Children's Cancer Group Multicentre Trial, JPLSG B-NHL-20).
Sekimizu M; Fukano R; Koga Y; Mitsui T; Fujita N; Mori T; Hori D; Tanaka M; Ohki K; Iwafuchi H; Nakazawa A; Mori T; Kobayashi R; Hashimoto H; M Saito A; Kamei M;
BMJ Open; 2024 Mar; 14(3):e080762. PubMed ID: 38508620
[TBL] [Abstract][Full Text] [Related]
7. Rituximab for High-Risk, Mature B-Cell Non-Hodgkin's Lymphoma in Children.
Minard-Colin V; Aupérin A; Pillon M; Burke GAA; Barkauskas DA; Wheatley K; Delgado RF; Alexander S; Uyttebroeck A; Bollard CM; Zsiros J; Csoka M; Kazanowska B; Chiang AK; Miles RR; Wotherspoon A; Adamson PC; Vassal G; Patte C; Gross TG; ;
N Engl J Med; 2020 Jun; 382(23):2207-2219. PubMed ID: 32492302
[TBL] [Abstract][Full Text] [Related]
8. High monocytic MDSC signature predicts multi-drug resistance and cancer relapse in non-Hodgkin lymphoma patients treated with R-CHOP.
Dhar S; Chakravarti M; Ganguly N; Saha A; Dasgupta S; Bera S; Sarkar A; Roy K; Das J; Bhuniya A; Ghosh S; Sarkar M; Hajra S; Banerjee S; Pal C; Saha B; Mukherjee KK; Baral R; Bose A
Front Immunol; 2023; 14():1303959. PubMed ID: 38304256
[TBL] [Abstract][Full Text] [Related]
9. Optimal dosage of rituximab for children with Burkitt lymphoma.
Huang S; Jin L; Yang J; Zhang M; Zhang Y; Peng Y; Duan Y; Zheng H
Ann Hematol; 2024 Mar; 103(3):893-903. PubMed ID: 38091052
[TBL] [Abstract][Full Text] [Related]
10. Novel CD20 monoclonal antibodies for lymphoma therapy.
Cang S; Mukhi N; Wang K; Liu D
J Hematol Oncol; 2012 Oct; 5():64. PubMed ID: 23057966
[TBL] [Abstract][Full Text] [Related]
11. [Efficacy and safety of rituximab in children and adolescents with mature B-cell non-Hodgkin's lymphoma: a Meta analysis].
Li BY; Han YH; Yin CY; DU WC; Li YF; Wang YC
Zhongguo Dang Dai Er Ke Za Zhi; 2023 Jan; 25(1):51-59. PubMed ID: 36655664
[TBL] [Abstract][Full Text] [Related]
12. Results from a Phase 1 Study of ACTR707 in Combination with Rituximab in Patients with Relapsed or Refractory CD20
Munoz J; Flinn IW; Cohen JB; Sachs J; Exter B; Ranger A; Harris P; Payumo F; Nath R; Hamadani M; Westin JR; Bachanova V
Transplant Cell Ther; 2024 Feb; 30(2):241.e1-241.e8. PubMed ID: 37898374
[TBL] [Abstract][Full Text] [Related]
13. The FACT-targeted drug CBL0137 enhances the effects of rituximab to inhibit B-cell non-Hodgkin's lymphoma tumor growth by promoting apoptosis and autophagy.
Lv Y; Du Y; Li K; Ma X; Wang J; Du T; Ma Y; Teng Y; Tang W; Ma R; Wu J; Wu J; Feng J
Cell Commun Signal; 2023 Jan; 21(1):16. PubMed ID: 36691066
[TBL] [Abstract][Full Text] [Related]
14. Retreatment with chimeric CD 20 monoclonal antibody in a patient with nodal marginal zone B-cell lymphoma.
Koh LP; Lim LC; Thng CH
Med Oncol; 2000 Aug; 17(3):225-8. PubMed ID: 10962535
[TBL] [Abstract][Full Text] [Related]
15. B-cell recovery following rituximab-based therapy is associated with perturbations in stromal derived factor-1 and granulocyte homeostasis.
Dunleavy K; Hakim F; Kim HK; Janik JE; Grant N; Nakayama T; White T; Wright G; Kwak L; Gress R; Tosato G; Wilson WH
Blood; 2005 Aug; 106(3):795-802. PubMed ID: 15718416
[TBL] [Abstract][Full Text] [Related]
16. High-dose methotrexate, thiotepa, orelabrutinib combined with or without rituximab in primary or secondary central nervous system diffuse large B-cell lymphoma: a single-center retrospective analysis.
Li Y; Li Y; Zeng R; He Y; Liang L; Ou L; Su C; Zhou H; Xiao L
J Cancer; 2023; 14(17):3182-3190. PubMed ID: 37928429
[No Abstract] [Full Text] [Related]
17. Rituximab in the treatment of non-Hodgkin's lymphoma.
Hauptrock B; Hess G
Biologics; 2008 Dec; 2(4):619-33. PubMed ID: 19707443
[TBL] [Abstract][Full Text] [Related]
18. Impact of Rituximab (Rituxan) on the Treatment of B-Cell Non-Hodgkin's Lymphoma.
Dotan E; Aggarwal C; Smith MR
P T; 2010 Mar; 35(3):148-57. PubMed ID: 20442809
[TBL] [Abstract][Full Text] [Related]
19. Primary bone lymphoma: Clinical presentation and therapeutic considerations.
Müller A; Dreyling M; Roeder F; Baur-Melnyk A; Knösel T; Klein A; Birkenmaier C; Jansson V; Dürr HR
J Bone Oncol; 2020 Dec; 25():100326. PubMed ID: 33083218
[TBL] [Abstract][Full Text] [Related]
20. Thalidomide plus chemotherapy exhibit enhanced efficacy in the clinical treatment of T-cell non-Hodgkin's lymphoma: A prospective study of 46 cases.
Wu H; Zhao C; Gu K; Jiao Y; Hao J; Sun G
Mol Clin Oncol; 2014 Sep; 2(5):695-700. PubMed ID: 25054032
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]